An industry for healthy lives

Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.

Best practices for vaccine market access

The vaccine market access has a unique feature, the recommendation phase, linked to the Public Health nature of vaccination.

Indeed, the introduction of new vaccines goes through national immunisation programs (NIPs) or vaccination calendars that ensure timely and sufficient immunisation coverage of large populations, which is critical to meet vaccination campaigns’ objectives.

In Europe, the decision to introduce/not to introduce a specific vaccine in the NIPs is taken at national level. To facilitate this decision, most European countries have recommending bodies also known as National Immunisation Technical Advisory Groups (NITAGs). The NITAGs provide recommendations on vaccination based on scientific, evidence-based evaluations. Recommendations from NITAGs are advisory and the final decision regarding NIPs is taken within the Ministry of Health.

Vaccines Europe is conducting a project which objective is to revise and compare NITAGs’ policies and decision-making processes for vaccine market access in both EU and non-EU countries. Through the intelligence and findings gathered during a comprehensive desk research and the set up of an Advisory Board the focus will be on defining the best practices identified that could improve access to vaccination in European countries.